Golimumab: A Review in Inflammatory Arthritis

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
James E Frampton

Abstract

Golimumab (Simponi®), a fully human monoclonal antibody against tumour necrosis factor-alpha (TNFα), is given once monthly by subcutaneous injection. In the EU, golimumab is approved as monotherapy and/or in combination with methotrexate for the treatment of inflammatory arthritis, including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis [comprising ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)] in adults, and polyarticular juvenile idiopathic arthritis (pJIA) in children. These approvals were based on the observations that golimumab was generally well tolerated and conferred some or all of the following benefits in pivotal studies in these settings: reduced signs and symptoms of arthritis; improved physical functioning and health-related quality of life; and slowed radiographic progression. Of note, data from long-term extensions (LTEs) of pivotal studies in RA, PsA and AS have confirmed that the safety and efficacy of golimumab are sustained through 5 years of treatment; the long-term tolerability profile of the drug is similar to that of other TNFα inhibitors (TNFis). Like other subcutaneous TNFis, golimumab offers patients the convenience and flexibilit...Continue Reading

References

Nov 7, 2006·Rheumatology·E L Williams, C J Edwards
Aug 30, 2007·Musculoskeletal Care·Frances Chilton, Raymond A Collett
Jun 6, 2009·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Vicki Oldfield, Greg L Plosker
May 5, 2011·Annals of the Rheumatic Diseases·J BraunD van der Heijde
Jul 2, 2011·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Ewen CumminsYogesh Suresh Punekar
Jan 31, 2012·PharmacoEconomics·Huiqin YangNerys Woolacott
Apr 17, 2012·The Journal of Rheumatology·Mark C GenoveseMahboob U Rahman
Jun 7, 2013·Annals of the Rheumatic Diseases·Bernard CombeUNKNOWN GO-MORE Investigators
Dec 21, 2013·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Mary Chester WaskoMahboob U Rahman
Nov 13, 2014·Clinical Drug Investigation·Alberto MiglioreLea Petrella
Feb 6, 2015·Wiener medizinische Wochenschrift·Helga Radner, Daniel Aletaha
Feb 18, 2015·Inflammopharmacology·Sandhya Jinesh
Jul 3, 2015·Therapeutic Advances in Chronic Disease·Eun Jin Kang, Arthur Kavanaugh
Aug 19, 2015·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Sarah S ThomasDaniel E Furst
Oct 18, 2015·Rheumatic Diseases Clinics of North America·Philip J Mease
Aug 2, 2016·Expert Review of Clinical Immunology·Mohammed S Osman, Walter P Maksymowych

❮ Previous
Next ❯

Citations

Sep 18, 2018·Expert Review of Clinical Immunology·Thorvardur Jon Love, Arthur Kavanaugh
May 25, 2020·European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·Jami Sayed AbdullaChanghao Liu
Mar 23, 2019·Journal of Clinical Medicine·Eleftherios PelechasAlexandros A Drosos
Jun 3, 2021·International Journal of Molecular Sciences·Eunhye Ji, Sahmin Lee

❮ Previous
Next ❯

Software Mentioned

RAISE
AFTER
MORE
GO
BEFORE
FORWARD
KIDS

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here